Fragment-based discovery of inhibitors of protein kinase B

Current Topics in Medicinal Chemistry

Volumn 9, Issue 18, 2009, Pages 1705-1717

  Davies, Thomas G ^b   Woodhead, Steven J ^b   Collins, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZAINDOLE DERIVATIVE; CCT 128930; CYCLIC AMP DEPENDENT PROTEIN KINASE; INDOLE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CRYSTALLOGRAPHY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FRAGMENT BASED DRUG DISCOVERY METHOD; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS; TUMOR; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; PROCEDURES; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74249105250     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609790102419     Document Type: Article

References (66)

1. Collins, I. Targeted small-molecule inhibitors of protein kinase B as anticancer agents. Anti-Cancer Agents Med. Chem. 2009, 9, 32-50.
2. Fayard, E.; Tinignac, L. A.; Baudry, A.; Hemmings, B. A. Protein kinase B/Akt at a glance. J. Cell Sci. 2005, 118, 5675-5678.
3. Thomas, C. C.; Deak, M.; Alessi, D. R.; Van Aalten, D. M. F. High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol 3,4,5-triphosphate. Curr. Biol. 2002, 12, 1256-1262.
4. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, N. C.; Alessi, D. R.; Van Aalten, D. M. F. Binding of phosphatidylinositol 3,4,5-triphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 2003, 375, 531-538.
5. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307, 1098-1101.
6. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3β-peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9, 940-944.
7. Hennessy, B. T.; Smith, D. L.; Prahlad, T. R.; Lu, Y.; Mills, G. B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4, 988-1004.
8. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24, 7842-7492.
9. Tokunaga, E.; Kimura, Y.; Oki, E.; Ueda, N.; Futatsugi, M.; Mashino, K.; Yamamoto, M.; Ikebe, M.; Kakeji, Y.; Baba, H.; Maehara, Y. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int. J. Cancer 2006, 118, 284-289.
10. Bader, A. G.; Khang, S.; Zhao, L.; Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 2005, 5, 921-929.
11. Cully, M.; You, H.; Levine, A. J.; Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6, 184-192.
12. Leslie, N. R.; Downes, C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 2004, 382, 1-11.
13. Testa, J. R.; Bellacosa, A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98, 10983-10985.
14. Carpten, J. D.; Faber, A. L.; Horn, C.; Donoho, G. P.; Briggs, S. L.; Robbins, C. M.; Hostetter, G.; Boguslawski, S.; Moses, T. Y.; Savage, S.; Uhlik, M.; Lin, A.; Du, J.; Qian, Y.; Zeckner, D. J.; Tucker-Kellog, G.; Touchman, J.; Patel, K.; Mousses, S.; Bittner, M.; Schevitz, R.; Lai, M. T.; Blanchard, K. L.; Thomas, J. E. A transforming mutation in the pleckstrin honology domain of AKT1 in cancer. Nature 2007, 448, 439-444.
15. Barnett, S. F.; Bilodeau, M. T.; Lindsley, C. W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr. Top. Med. Chem. 2005, 5, 109-125.
16. Lindsley, C. W.; Barnett, S. F.; Yaroschak, M.; Bilodeau, M. T.; Layton, M. E. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr. Top. Med. Chem. 2007, 7, 1349-1363.
17. Heerding, D. A.; Safonov, I. G.; Verma, S. K. Small molecule inhibitors of AKT/PKB kinase as a strategy for treating cancer. Ann. Rep. Med. Chem. 2007, 42, 365-376.
18. Li, Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. Ther. Pat. 2007, 17, 1077-1130.
19. Li, Q.; Li, T.; Zhu, G.; Gong, J.; Claiborne, A.; Dalton, C.; Luo, Y.; Johnson, E. F.; Shi, Y.; Liu, X.; Klinghofer, V.; Bauch, J. L.; Marsh, K. C.; Bouska, J. J.; Arries, S.; De Jong, R.; Oltersdorf, T.; Stoll, V. S.; Jakob, C. G.; Rosenberg, S. H.; Giranda, V. L. Discovery of trans-3,4'- bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/AKT) for the treatment of cancer. Bioorg. Med. Chem. Lett. 2006, 16, 1679-1685.
20. Lippa, B.; Pan, G.; Corbett, M.; Li, C.; Kauffman, G. S.; Pandit, J.; Robinson, S.; Wei, L.; Kozina, E.; Marr, E. S.; Borzillo, G.; Knauth, E.; Barbacci-Tobin, P. V.; Troutman, M.; Baker, D.; Kakar, S.; Clark, T.; Morris, J. Synthesis and structure-based optimization of novel Akt inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3359-3363.
21. Burns, S.; Travers, J.; Collins, I.; Rowlands, M. G.; Newbatt, Y.; Thompson, N.; Garrett, M. D.; Workman, P.; Aherne, W. Identification of small molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreen™ high-throughput screen. J. Biomol. Screen. 2006, 11, 822-827.
22. Lin, X.; Murray, J. M.; Rico, A.C.; Wang, M. X.; Chu, D. T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A. B. Discovery of 2-pyrimidyl-5-aminothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg. Med. Chem. Lett. 2006, 16, 4163-4168.
23. Breitenlechner, C. B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R. A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem. 2004, 47, 1375-1390.
24. Reuveni, H.; Livnah, N.; Geiger, T.; Klein, S.; Ohne, O.; Cohen, I.; Benhar, M.; Gellerman, G.; Levitzki, A. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002, 41, 10304-10314.
25. Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Hunter, L. K.; Garrett, M. D.; Rowlands, M. G.; Aherne, G. W.; Davies, T. G.; Berdini, V.; Woodhead, S. J.; Davis, D.; Seavers, L. C. A.; Wyatt, P. G.; Workman, P.; McDonald, E. Structure-based design of iosquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg. Med. Chem. 2006, 14, 1255-1273.
26. Li, Q.; Woods, K. W.; Thomas, S.; Zhu, G.; Packard, G.; Fisher, J.; Li, T.; Gong, J.; Dinges, J.; Song, X.; Abrams, J.; Luo, Y.; Johnson, E. F.; Shi, Y.; Liu, X.; Klinghofer, V.; Des Jong, R.; Oltersdorf, T.; Stoll, V. S.; Jakob, C. G.; Rosenberg, S. H.; Giranda, V. L. Synthesis and structure-activity relationship of 3,4′-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorg. Med. Chem. Lett. 2006, 16, 2000-2007.
27. Luo, Y.; Shoemaker, A. R.; Liu, X.; Woods, K. W.; Thomas, S. A.; de Jong, R.; Kan, E. H.; Li, T.; Stoll, V. S.; Powlas, J. A.; Oleksijew, A.; Mitten, M. J.; Shi, Y.; Guan, R.; McGonigal, T. P.; Klinghofer, V.; Johnson, E. F.; Leverson, J. D.; Bouska, J. J.; Mamo, M.; Smith, R. A.; Gramling-Evans, E. E.; Zinker, B. A.; Mika, A. K.; Nguyen, P. T.; Oltersdorf, T.; Rosenberg, S. H.; Li, Q.; Giranda, V. L. Potent and selective inhibitors of Akt kinases slow the progress of tumours in vivo. Mol. Cancer Ther. 2005, 4, 977-986.
28. Gaßel M.; Breitenleichner, C. B.; Rüger, P.; Jucknischke, U.; Schneider, T.; Huber, R.; Bossemeyer, D.; Engh, R. A. Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J. Mol. Biol., 2003, 329, 1021-1034.
29. Breitenlechner, C. B.; Friebe, W.; Brunet, E.; Werner, G.; Graul, K.; Thomas, U.; Künkele, K.; Schäfer, W.; Gassel, M.; Bossemeyer, D.; Huber, R.; Engh, R. A.; Masjost, B. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J. Med. Chem. 2005, 48, 163-170.
30. Gills, J. J.; Dennis, P. A. The development of phosphatidylinositol etther lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Investig. Drugs 2004, 13, 787-797.
31. Qiao, L.; Nan, F.; Kunkel, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-Deoxy-D-myoinositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signalling and cancer cell growth. J. Med. Chem. 1998, 41, 3303-3306.
32. Hu, Y.; Qiao, L.; Wang, S.; Rong, S.; Meuillet, E. J.; Bergren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J. Med. Chem. 2000, 43, 3045-3051.
33. Kozikowski, A. P.; Sun, H.; Brognard, J.; Dennis, P. A. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J. Am. Chem. Soc. 2003, 125, 1144-1145.
34. Maffucci, T.; Piccolo, E.; Cumashi, A.; Iezzi, M.; Riley, A. M.; Saiardi, A.; Godage, H. Y.; Rossi, C.; Broggini, M.; Iacobelli, S.; Potter, B. V. L.; Innocenti, P.; Falasca, M. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res. 2005, 65, 8339-8349.
35. Mill, S. J.; Komander, D.; Trusselle, M. N.; Safrany, S. T.; van Aalten, D. M. F.; Potter, B. V. L. Novel inositol phospholipid head-group surrogate crystallised in the pleckstrin homology domain of protein kinase Balpha. Chem. Biol. 2007, 2, 242-246.
36. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 761-764.
37. Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 905-909.
38. Bilodeau, M. T.; Balitza, A. E.; Hoffman, J. M.; Manley, P. J.; Barnett. S. F.; Defeo-Jones, D.; Haskell. K.; Jones, R. E.; Leander, K.; Robinson, R. G.; Smith, A. M.; Huber, H. E.; Hartman, G. D. Allosteric inhibitors of Akt1 and Akt2: a naphthyridone with efficacy in an A2780 tumor xenograft model. Bioorg. Med. Chem. Lett. 2008, 18, 3178-3182.
39. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hanock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A. M.; Leander, K.; Lee, L. L.; Malinowski, J.; McAvoy, E. M.; Nahas, D. D.; Robinson, R. G.; Huber, H. E. Identification and characterisation of pleckstrin-homology-domain-dependent and isozyme-specific Akt inhibitors. Biochem. J. 2005, 385, 399-408.
40. Calleja, V.; Laguerre, M.; Parker, P. J.; Larijani, B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol. 2009, 7, e1000017.
41. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
42. Mooij, W. T.; Hartshorn, M. J.; Tickle, I. J.; Shariff, A. J.; Verdonk, M. L.; Jhoti, H. Automated protein-ligand crystallography for structure-based drug design. ChemMedChem. 2006, 1, 827-838.
43. Davies, T. G.; Verdonk, M. L.; Graham, B.; Saalau-Bethell, S.; Hamlett, C. C.; McHardy, T.; Collins, I.; Garrett, M. D.; Workman, P.; Woodhead, S. J.; Jhoti, H.; Barford, D. A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. 2007, 367, 882-894.
44. Congreve, M.; Carr, R.; Murray. C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 2003, 8, 876-877.
45. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 2004, 8, 660-672.
46. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431.
47. Donald, A.; McHardy, T.; Rowlands, M. G.; Hunter, L. K.; Davies, T. G.; Berdini, V.; Boyle, R. G.; Aherne, G. W.; Garrett, M. D.; Collins, I. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B (PKB/Akt) through structure-based design. J. Med. Chem. 2007, 50, 2289-2292.
48. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of novel inhibitors of protein kinase B (Akt) using fragment-based lead discovery. J. Med. Chem. 2007, 50, 2293-2296.
49. Caldwell, J. J.; Davies, T. G.; Donald, A.; McHardy, T.; Rowlands, M. G.; Aherne, G. W.; Hunter, L. K.; Taylor, K.; Ruddle, R.; Raynaud, F. I.; Verdonk, M.; Workman, P.; Garrett, M. D.; Collins, I. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J. Med. Chem. 2008, 51, 2147-2157.
50. Rejto, P. A.; Verkhiver, G. M. Unravelling the principles of lead discovery: from frustrated energy landscapes to novel molecular anchors. Proc. Natl. Acad. Sci. USA 1996, 93, 8945-8950.
51. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2006, 2, 720-723.
52. Verdonk, M. L.; Rees, D. C. Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem. 2008, 3, 1179-1180.
53. Caldwell, J. J.; Cheung, K.-M.; Collins, I. Synthesis of 4-(cyclic dialkylamino)-7-azaindoles by microwave heating of 4-halo-7-azaindoles and cyclic secondary amines. Tetrahedron Lett. 2007, 48, 1527-1529.
54. Vlietstra, R. J.; van Alewijk, D. C.; Hermans, K. G.; van Steenbrugge, G. J.; Trapman, J. Frequent inactivations of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 68, 2720-2723.
55. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmed, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterisation of a potent inhibitor of class I phosphatidylinositol 3-kinases. Cancer Res. 2007, 67, 5840-5850.
56. Gowan, S. M.; Hardcastle, A.; Halsworth, A. E.; Valenti, M. R.; Hunter, L.-J. K.; de Haven Brandon, A. K.; Garrett, M. D.; Raynaud, F. I.; Workman, P.; Aherne, W.; Eccles, S. A. Application of Meso Scale technology for the measurement of phosphorproteins in human tumour xenografts. Assay Drug Dev. Technol. 2007, 5, 391-401.
57. Grimshaw, K.; Hunter, L. K.; Yap, T. A.; Heaton, S.; Woodhead, S.; Davies, T.; Thompson, N.; Workman, P.; Garrett, M. D. Manuscript submitted.
58. Bossi, I.; Stratakis, C. A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 2004, 145, 5452-5458.
59. Bossis, I.; Voutetakis, A.; Bei, T.; Sandrini, F.; Griffin, K. J.; Stratakis, C. A. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr. Relat. Cancer 2004, 11, 265-280.
60. Harrington, L. S.; Findlay, G. M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N. R.; Cheng, S.; Shepherd, P. R.; Gout, I.; Downes, C. P.; Lamb, R. F. The TSC1-2 tumour suppressor controls insulin signalling via regulation of IRS proteins. J. Cell Biol. 2004, 166, 213-223.
61. Han, E. K.; Leverson, J. D.; McGonigal, T.; Shah, O. J.; Woods, K. W.; Hunter, T.; Giranda, V. L.; Luo, Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phophorylation independent of mTORC1 inhibition. Oncogene 2007, 26, 5655-5661.
62. Okuzumi, T.; Fiedler, D.; Zhang, C.; Gray, D. C.; Aizenstein, B.; Hoffman, R.; Shokat, K. M. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 2009, 5, 484-493.
63. Gribble, F. M.; Loussouarn, G.; Tucker, S. J.; Zhao, C.; Nichols, C. G.; Ashcroft, F. M. A novel method for measurement of submembrane ATP concentration. J. Biol. Chem. 2000, 275, 30046-30049.
64. Traut, T. W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 1994, 140, 1-22.
65. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
66. Smyth, L. A.; Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. J. Chem. Biol. 2009, 2, 131-151.